Montelucaste Alter (Montelukast)

Montelukast acts on the leukotriene pathway to control respiratory and allergic conditions.

• Asthma prophylaxis: reduces the frequency and severity of asthma attacks when used regularly.
• Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.
• Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergies.

• Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and F4 from binding. This inhibition reduces bronchoconstriction, vascular permeability, mucus secretion, and inflammatory cell recruitment in the airways, thereby improving respiratory function and decreasing allergic inflammation.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate pain often reported.
• Abdominal pain: discomfort or cramping in the stomach area.
• Cough: occasional dry cough.
• Fever: low‑grade temperature elevation.
• Sore throat: irritation or pain in the throat.
• Dizziness: feeling light‑headed or unsteady.

Serious or Rare Side Effects

• Allergic reactions: rash, angioedema, or anaphylaxis.
• Neuropsychiatric events: agitation, depression, or suicidal thoughts.
• Hepatic injury: elevated liver enzymes or hepatitis.
• Blood disorders: neutropenia or eosinophilia.
• Stevens‑Johnson syndrome: severe skin blistering.
• Severe asthma exacerbation: paradoxical worsening of symptoms.

Before prescribing Montelucaste Alter, clinicians should consider several safety aspects.

• Assess asthma control: ensure baseline therapy is optimized.
• Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation.
• Use with caution in hepatic impairment: dose adjustment may be required.
• Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
• Review concomitant medications: consider potential drug interactions.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may raise montelukast plasma levels.
• Concurrent leukotriene modifiers (e.g., zafirlukast, zileuton): increase risk of adverse effects.
• Phenobarbital: may markedly decrease montelukast exposure.

Moderate Interactions (Monitor Closely)

• CYP2C9 inhibitors (e.g., fluconazole): may modestly increase exposure.
• Warfarin: monitor INR as montelukast can affect anticoagulation.
• Antidepressants: observe for enhanced neuropsychiatric symptoms.